Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Nov 13

PMID 34771695

Citations 26

Authors

Kostas Palamaris

Evangelos Felekouras

Stratigoula Sakellariou

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies, characterized by aggressive biological behavior and a lack of response to currently available chemotherapy. Emerging evidence has identified epithelial to mesenchymal transition (EMT) as a key driver of PDAC progression and a central regulator in the development of drug resistance. EMT is a reversible transdifferentiation process controlled by complex interactions between multiple signaling pathways such as TGFb, Wnt, and Notch, which converge to a network of specific transcription factors. Activation of EMT transcriptional reprogramming converts cancer cells of epithelial differentiation into a more mesenchymal phenotypic state. EMT occurrence in pre-invasive pancreatic lesions has been implicated in early PDAC dissemination. Moreover, cancer cell phenotypic plasticity driven by EMT contributes to intratumoral heterogeneity and drug tolerance and is mechanistically associated with the emergence of cells exhibiting cancer stem cells (CSCs) phenotype. In this review we summarize the available data on the signaling cascades regulating EMT and the molecular isnteractions between pancreatic cancer and stromal cells that activate them. In addition, we provide a link between EMT, tumor progression, and chemoresistance in PDAC.

Citing Articles

MCT4: a key player influencing gastric cancer metastasis and participating in the regulation of the metastatic immune microenvironment.

Jiang T, Zhang J, Zhao S, Zhang M, Wei Y, Liu X J Transl Med. 2025; 23(1):276.

PMID: 40045374 PMC: 11884109. DOI: 10.1186/s12967-025-06279-8.

Aberrant expression of collagen type X in solid tumor stroma is associated with EMT, immunosuppressive and pro-metastatic pathways, bone marrow stromal cell signatures, and poor survival prognosis.

Famili-Youth E, Famili-Youth A, Yang D, Siddique A, Wu E, Liu W BMC Cancer. 2025; 25(1):247.

PMID: 39939916 PMC: 11823173. DOI: 10.1186/s12885-025-13641-y.

Smad2 Cooperating with TGIF2 Contributes to EMT and Cancer Stem Cells Properties in Pancreatic Cancer via Co-Targeting SOX2.

Zu F, Chen C, Geng Q, Li H, Chan B, Luo G Int J Biol Sci. 2025; 21(2):524-543.

PMID: 39781447 PMC: 11705628. DOI: 10.7150/ijbs.102381.

Vitamin D and Pancreatic Ductal Adenocarcinoma-A Review of a Complicated Relationship.

Grosu I, Constantinescu A, Balta M, Bajenaru O, Nuta C, Pavel C Nutrients. 2024; 16(23).

PMID: 39683479 PMC: 11643276. DOI: 10.3390/nu16234085.

Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma.

Kluz N, Kraj L, Chmiel P, Przybylkowski A, Wyrwicz L, Stec R Cancers (Basel). 2024; 16(23).

PMID: 39682132 PMC: 11640600. DOI: 10.3390/cancers16233945.

References

De Jesus-Acosta A, Sugar E, ODwyer P, Ramanathan R, Von Hoff D, Rasheed Z . Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Br J Cancer. 2019; 122(4):498-505. PMC: 7029016. DOI: 10.1038/s41416-019-0683-3. View

Scheibner K, Bakhti M, Bastidas-Ponce A, Lickert H . Wnt signaling: implications in endoderm development and pancreas organogenesis. Curr Opin Cell Biol. 2019; 61:48-55. DOI: 10.1016/j.ceb.2019.07.002. View

Feng H, Wei B, Zhang Y . Long non-coding RNA HULC promotes proliferation, migration and invasion of pancreatic cancer cells by down-regulating microRNA-15a. Int J Biol Macromol. 2018; 126:891-898. DOI: 10.1016/j.ijbiomac.2018.12.238. View

. Correction: IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. Clin Cancer Res. 2017; 23(3):868. DOI: 10.1158/1078-0432.CCR-16-1832. View

Dardare J, Witz A, Merlin J, Bochnakian A, Toussaint P, Gilson P . Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities. Pharmaceuticals (Basel). 2021; 14(8). PMC: 8399337. DOI: 10.3390/ph14080740. View

Lobry C, Oh P, Aifantis I . Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med. 2011; 208(10):1931-5. PMC: 3182047. DOI: 10.1084/jem.20111855. View

Lugli A, Zlobec I, Berger M, Kirsch R, Nagtegaal I . Tumour budding in solid cancers. Nat Rev Clin Oncol. 2020; 18(2):101-115. DOI: 10.1038/s41571-020-0422-y. View

Wartenberg M, Zlobec I, Perren A, Koelzer V, Gloor B, Lugli A . Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma. Oncotarget. 2015; 6(6):4190-201. PMC: 4414182. DOI: 10.18632/oncotarget.2775. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

10.

Fukuda A, Wang S, Morris 4th J, Folias A, Liou A, Kim G . Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell. 2011; 19(4):441-55. PMC: 3075548. DOI: 10.1016/j.ccr.2011.03.002. View

11.

Kyuno T, Kohno T, Konno T, Yamaguchi H, Kyuno D, Imamura M . Glucose-Dependent FOXM1 Promotes Epithelial-to-Mesenchymal Transition Via Cellular Metabolism and Targeting Snail in Human Pancreatic Cancer. Pancreas. 2020; 49(2):273-280. DOI: 10.1097/MPA.0000000000001485. View

12.

Liu C, Cheng H, Shi S, Cui X, Yang J, Chen L . MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3. Curr Mol Med. 2013; 13(4):467-78. DOI: 10.2174/1566524011313040001. View

13.

Oskarsson T, Batlle E, Massague J . Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014; 14(3):306-21. PMC: 3998185. DOI: 10.1016/j.stem.2014.02.002. View

14.

Briscoe J, Therond P . The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013; 14(7):416-29. DOI: 10.1038/nrm3598. View

15.

Ozdemir B, Pentcheva-Hoang T, Carstens J, Zheng X, Wu C, Simpson T . Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014; 25(6):719-34. PMC: 4180632. DOI: 10.1016/j.ccr.2014.04.005. View

16.

Zhang D, Li L, Jiang H, Knolhoff B, Lockhart A, Wang-Gillam A . Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2016; 23(7):1748-1759. PMC: 5378683. DOI: 10.1158/1078-0432.CCR-16-1121. View

17.

Rao C, Mohammed A . New insights into pancreatic cancer stem cells. World J Stem Cells. 2015; 7(3):547-55. PMC: 4404390. DOI: 10.4252/wjsc.v7.i3.547. View

18.

Xie D, Cui J, Xia T, Jia Z, Wang L, Wei W . Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression. Oncotarget. 2015; 6(34):35949-63. PMC: 4742153. DOI: 10.18632/oncotarget.5772. View

19.

Attramadal C, Kumar S, Boysen M, Dhakal H, Nesland J, Bryne M . Tumor Budding, EMT and Cancer Stem Cells in T1-2/N0 Oral Squamous Cell Carcinomas. Anticancer Res. 2015; 35(11):6111-20. View

20.

Nagathihalli N, Castellanos J, VanSaun M, Dai X, Ambrose M, Guo Q . Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells. Oncotarget. 2016; 7(40):65982-65992. PMC: 5323208. DOI: 10.18632/oncotarget.11786. View